Echolight srl was officially incorporated by the founding team with a revolutionary idea: developing the first radiation-free device for early diagnosis of osteoporosis at the lumbar vertebrae and the femoral neck.
It is officially filed the first patent of R.E.M.S. technology: an innovative echographic approach for bone micro-architecture characterization.
Life Science Capital
Life Science Capital S.p.a., an italian investment company in the medical device sector, invests in Echolight to support and speed up the research and development activities of the company..
The first version of Echos is finalized: the only radiation free device for bone densitometry at the lumbar vertebrae and the femoral neck. A decisive step towards a new era in the early diagnosis of osteoporosis and bone health assessment.
In collaboration with the National Council of Research the first multi-center study for the clinical validation of R.E.M.S. technology in the most important reference centers for the diagnosis of osteoporosis is launched.
Echolight secured all the standard certifications: UNI CEI EN ISO 13485: 2012, ISO 13485: 2003, UNI EN ISO 9001: 2008 Quality Management System and the CE mark for Echos, EchoStation and EchoStudio by KIWA CERMET.
Echolight introduces to the international medical community the latest release of Echos at the World Congress of Osteoporosis.
Panakès and Invitalia Ventures have co-led an investment round in Echolight, in order to support the clinical validation of the innovative technology and the worldwide launch of the product.
Scientific Advisory Board
Echolight established the new international scientific advisory board with the most important medical personalities in the diagnosis of osteoporosis.
Echolight at the International Trade Fair MEDICA launched Echos after extensive research and development activities carried out over the last eight years.
Echolight S.p.A. has received 510(k) clearance from the Food and Drug Administration (FDA) to market its range of products in the U.S.A.
Milestone pubblication on Osteoporosis International about R.E.M.S. Multicenter Clinical Trial: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.”
Echolight obtained a Consensus Paper from ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, on R.E.M.S. technology.
Worldwide sales network
Echolight in less than three years has a sales network of 40 distributors and several hundred satisfied customers all over the world.”
Imagination. Knowledge. Innovation.
We secured all the standard certifications: UNI CEI EN ISO 13485: 2016,
UNI EN ISO 9001: 2015 Quality Management System, CE Mark, FDA Clearence
and other main certifications all over the world for our innovative solutions.
Research & Dreams
In collaboration with the National Council of Research, we carried out
international multi-center studies for the clinical validation of the proprietary
technology in the most important reference centers for the diagnosis of osteoporosis
under the lead of our prestigious scientific advisory board.
International scientific advisory board
Prof. Maria Luisa Brandi
Director of Bone Mineral and
Metabolism diseases Unit at
Careggi Hospital in Florence.
Prof. of Endocrinology
Univeristy of Florence.
Prof. Jean-Yves Reginster
Head of the bone and
cartilage, Metabolism Unit.
University of Liegi
Prof. Cyrus Cooper
Professor of Rheumatology
University of Southampton
Southampton General Hospital
Prof. Adolfo Diez-Perez
Hospital del Mar
Prof. René Rizzoli
Emeritus Professor of Medicine
University Hospitals and
Faculty of Medicine.
Prof. Bernard Cortet
President of the GRIO
Scientific Board of Paris.
Professor in Rheumatology
Roger Salengro Hospital
Chu de Lille, France.
Around the globe
Echolight, a growing med-tech company located in Italy,
in less than three years has a sales network of 40 distributors
and several hundred satisfied customers all over the world.